The Institute of Molecular Biology has the institutional mission of meeting the demands for improvements in Health with excellence and priority,generating knowledge and production of inputs to primarily serve the SUS. The institute develops products that enable diagnoses of socially and financially costly diseases for the national health system. This is possible because of the proximity of the Institute with Oswaldo Cruz Foundation (Fiocruz) and other national and international research and development centers, funding agencies, and reference hospitals.

In IBMP, technological development seeks to technologically dominate areas necessary to obtain products for in-vitro diagnosis. Recently, the Institute began to act in order to obtain and apply therapeutic molecules for chronic degenerative diseases, tissue regeneration, and aesthetics.


Immunoassay diagnostic tests

Diagnostic tests that detect the immune response, using platforms that allow the delivery of the result in less than 20 minutes and facilitate immediate treatment or monitoring of infectious diseases such as HIV, HBV, HCV, syphilis and Chagas disease, among others.

Molecular diagnostic tests

The real-time PCR platform serves as the basis for promoting the development of highly accurate and sensitive diagnoses by detecting DNA or RNA from selected targets. This platform is complementary to the detection of the immune response since it is also suitable as a possibility for the detection of pathogens before the host has antibodies responding to the pathogenic organism.

Personalized medicine

Technological development area in which IBMP operates and is related to diagnostic tests that use genetic characteristics for individualized diagnoses in patients and prescription of the appropriate treatment as soon as possible.

Therapeutic solutions: Biomolecules

IBMP has as one of its objectives to master the technological competence in the development of molecules and processes used to treat diseases. Examples of such molecules are proteins and antibodies. Through this new competence, it is sought to reduce the cost and increase the accessibility to several therapeutic proteins of great importance for public health.